Delivery Order SPE2DB22D3301-SPE2DB25FZ1SJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $25,590.70 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) on September 24, 2025, with completion scheduled for September 25, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive procurement process. The contractor will perform this work at its corporate office location in Conshohocken, Pennsylvania, providing pharmaceutical products to...
- The Defense Logistics Agency awarded a delivery order valued at $6,642.00 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitive award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a firm fixed-price transaction with no set-aside designation. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ondansetron HCl 4 mg tablets (500 count) with a contract value of $8,155.72. This is a firm fixed-price delivery order under a competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is one of the federal government's primary pharmaceutical distributors and serves as a critical vendor for military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ondansetron HCL 4 mg tablets (30-count packaging) with a contract value of $3,436.96. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract has an ultimate completion date...
- The Defense Logistics Agency awarded a delivery order valued at $3,759.95 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets in quantities of 30, with an ultimate completion date of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be performed from the contractor's facility...
- The Defense Logistics Agency awarded a delivery order valued at $2,181.96 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This competitive, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The delivery order represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $5,956.09 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets in quantities of 30 units. This competitive award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order valued at $3,168.39 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, with performance to be completed by July 18, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $7,201.78 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg on July 21, 2025, with completion expected by July 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and supplies a comprehensive range of...
- The Defense Logistics Agency awarded a delivery order valued at $5,153.60 to AmerisourceBergen Drug Corp for Ondansetron HCL 8 mg tablets (30-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price, competitively awarded delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the pharmaceutical supply chain support that...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ1SJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $212,889.17 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets in quantities of 500 units. This firm fixed price, competitively awarded delivery order is set to be completed by September 30, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a non-set-aside award, indicating the vendor competed against other qualified suppliers in an open procurement process. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. This comprehensive global pharmaceutical support vehicle enables the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including support for the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen's position as a prime vendor reflects its established capability to meet federal pharmaceutical procurement requirements and supply critical medical commodities across multiple therapeutic domains to support military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $212.9k | 9/29/25 |